Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROGESTIN 1.5/30 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, preventing ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Acne vulgaris (off-label, for women who desire contraception and have not responded to topical therapy),Dysmenorrhea (off-label),Endometriosis (off-label),Menorrhagia (off-label),Functional ovarian cysts (off-label)
Prevention of pregnancy (FDA-approved)
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-19 hours. Steady-state reached within 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Norethindrone acetate is deacetylated to norethindrone, primarily metabolized via cytochrome P450 3A4 (CYP3A4) to reduced metabolites, sulfates, and glucuronides. Ethinyl estradiol is metabolized primarily by CYP3A4, undergoes hydroxylation, and undergoes conjugation (glucuronidation and sulfation). Both undergo enterohepatic recirculation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50-60% (primarily as glucuronide conjugates of ethinyl estradiol and norethindrone); Fecal: ~40-50% (via biliary elimination)
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 90-95% bound to SHBG and albumin; Ethinyl estradiol: 95-98% bound to albumin, with 2-5% free.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 3-5 L/kg; Ethinyl estradiol: 2-4 L/kg. High Vd indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norethindrone ~64-75%; Ethinyl estradiol ~45-60% due to first-pass metabolism.
Oral: ~70% due to first-pass metabolism.
No dose adjustment is required for patients with renal impairment. However, because of potential fluid retention, use with caution in patients with renal dysfunction.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with acute liver disease or hepatocellular carcinoma. For Child-Pugh class A: use with caution; class B or C: not recommended due to potential for impaired hormone metabolism.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and effectiveness in pediatric patients under 18 years have not been established. Not indicated for use before menarche.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific dosing recommendations in elderly; evaluate risk-benefit considering comorbidities (e.g., cardiovascular disease).
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events (thrombophlebitis, venous thromboembolism, stroke, myocardial infarction) from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (venous thromboembolism, arterial thrombosis), stroke, myocardial infarction, especially in smokers >35 years. Hepatic neoplasia (benign and malignant), hypertension, gallbladder disease, carbohydrate/lipid effects, headache/migraine exacerbation, visual disturbances (retinal thrombosis). Breakthrough bleeding/spotting. Hepatic enzyme induction (e.g., rifampin) may reduce contraceptive efficacy.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Active or history of thrombophlebitis or thromboembolic disorders. Cerebrovascular or coronary artery disease. Known or suspected pregnancy. Undiagnosed abnormal uterine bleeding. Known or suspected breast carcinoma or other estrogen-/progestin-sensitive neoplasia. Hepatic adenoma or carcinoma. Jaundice or cholestatic jaundice of pregnancy, or history of jaundice with prior oral contraceptive use. Acute or chronic hepatocellular disease with abnormal liver function. Heavy smoking (≥15 cigarettes/day) in women >35 years. Hypersensitivity to any component.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but no specific restriction. Consistent dietary habits are recommended to avoid cycle irregularities.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: An increased risk of cardiovascular defects and oral clefts following first-trimester exposure to oral contraceptives has been suggested but not confirmed. Norethindrone and ethinyl estradiol are not recommended during pregnancy. If pregnancy occurs, the drug should be discontinued. Second and third trimesters: Exposure to estrogens and progestins may cause fetal harm, including urogenital abnormalities in female fetuses (e.g., hypospadias in males, clitoral enlargement, labial fusion in females). Use is contraindicated during known or suspected pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of oral contraceptive steroids (including norethindrone and ethinyl estradiol) are excreted in breast milk. The M/P ratio is approximately 0.5 for norethindrone and 0.01–0.02 for ethinyl estradiol. Use during lactation may decrease milk production and quality. Not recommended for use in nursing mothers until weaning is complete. Alternative methods of contraception should be considered.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dosing adjustment is applicable as the drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism) are not relevant since use is contraindicated. Inadvertent exposure should prompt discontinuation and evaluation.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
MICROGESTIN 1.5/30 (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) is a monophasic combined oral contraceptive. Its progestin component has mild androgenic activity, which may benefit some women with acne. Bleeding irregularities are common in the first 3 cycles. Counsel patients that missing pills increases pregnancy risk; strict adherence is critical. Evaluate baseline blood pressure and consider stopping if migraine with aura develops. Liver enzyme inducers (e.g., rifampin, certain anticonvulsants) may reduce efficacy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time to maintain steady hormone levels.,If you miss a pill, refer to the package insert: take the missed pill as soon as remembered and use backup contraception (e.g., condoms) for 7 days.,Common side effects include nausea, breast tenderness, and spotting; these often improve after 3 cycles.,Smoking increases risk of serious cardiovascular side effects, especially if over 35 years old and smoking 15+ cigarettes daily.,Seek emergency care for leg pain/swelling, sudden severe headache, chest pain, or vision changes (possible blood clot or stroke).
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROGESTIN 1.5/30 vs AFIRMELLE, answered by our medical review team.
MICROGESTIN 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, preventing ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROGESTIN 1.5/30 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROGESTIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROGESTIN 1.5/30 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROGESTIN 1.5/30 is classified as Category C. First trimester: An increased risk of cardiovascular defects and oral clefts following first-trimester exposure to oral contraceptives has been suggested but not confirmed. Norethi. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.